GHRL and neuroendocrine neoplasm: Indeed, results from our group have demonstrated that oncogenic splicing variants from somatostatin and ghrelin systems (SST5TMD4/5 and In1-ghrelin) are poorly expressed in normal tissue but highly expressed in neuroendocrine tumors (NETs), including PitNETs [17,18,19,20,30,31], where they increase aggressiveness features.